Rein Therapeutics’ LTI-03 advances in Phase II IPF study
LTI-03, an IPF drug candidate, is progressing through a Phase II trial that is enrolling ahead of schedule, with dual-action claims to inhibit fibrosis and preserve lung progenitor cells.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.